Effect of an 8‐Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi‐Center, Triple‐Blind, Randomized, Placebo‐Controlled Trial
Molecular Nutrition & Food Research · 2025
DOI: 10.1002/mnfr.70081 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Molecular Nutrition & Food Research, 2025. Verfasst von Reeta Ala-Jaakkola und 12 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences, International Flavors & Fragrances, Kantvik, Finland. Hauptthemen laut MEDLINE: Constipation, Bifidobacterium animalis, Probiotics, Dietary Supplements. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Danisco Sweeteners Oy (Affiliated to International Flavors & Fragrances, IFF).
Abstract (Originalsprache)
Functional constipation (FC) is characterized by difficult, infrequent, or incomplete bowel movements without clear physiological cause. Daily intake of Bifidobacterium lactis HN019 has been shown to reduce colonic transit time or increases bowel movement frequency in 2–4 weeks interventions. This triple‐blind, randomized, placebo‐controlled clinical trial assessed the effect of 8 weeks HN019 supplementation on complete spontaneous bowel movement (CSBMs) in adults with FC (diagnosed by Rome III criteria). Furthermore, stool consistency, degree of straining, abdominal pain severity, bloating severity, PAC‐SYM, PAC‐QoL, and use of rescue medication were assessed. Participants were screened at four clinical units in France for 2 weeks to confirm eligibility: no safety concerns, ≤3 CSBMs/week (recorded in daily diaries), followed by an 8‐week intervention with daily supplementation of HN019 or placebo. HN019 was not found to be superior in managing FC compared to placebo. Fecal samples were collected from 50% of the participants for analyses of moisture content, microbiota, microbial metabolites, and calprotectin. These did not show any significant differences between the groups. This study did not support the expected effect of HN019 on improving CSBM frequency in participants with FC. No safety concerns related to B. lactis HN019 supplementation were identified. Trial Registration: ClinicalTrial.gov: NCT04231162
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Sciences, International Flavors & Fragrances, Kantvik, Finland.
- Biofortis, route de la chatterie, Herblain, France.
- CEN NUTRIMENT, Impasse Françoise Dolto, Dijon, France.
- Institut Pasteur de Lille (IPL), Lille, France.
- Eurofins Optimed SAS, Gières, France.
- EstiMates Oy, Espoo, Finland.
ORCID-Profile: Sofia D Forssten
Förderung
- Danisco Sweeteners Oy (Affiliated to International Flavors & Fragrances, IFF)
Zitieren
APA
Ala-Jaakkola, R., Forssten, S. D., Cheng, J., Griffon, F., Metreau, I., Sturm, Y., Lecerf, J. M., Donazzolo, Y., Junnila, J., Nordlund, A., Hibberd, A., Ouwehand, A. C., & Ibarra, A. (2025). Effect of an 8‐Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi‐Center, Triple‐Blind, Randomized, Placebo‐Controlled Trial. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.70081
Vancouver
Ala-Jaakkola R, Forssten SD, Cheng J, Griffon F, Metreau I, Sturm Y, et al. Effect of an 8‐Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi‐Center, Triple‐Blind, Randomized, Placebo‐Controlled Trial. Molecular Nutrition & Food Research. 2025. doi:10.1002/mnfr.70081
BibTeX
@article{AlaJaakkola2025,
author = {Ala-Jaakkola, Reeta and Forssten, Sofia D and Cheng, Jing and Griffon, Flavie and Metreau, Isabelle and Sturm, Yves and Lecerf, Jean-Michel and Donazzolo, Yves and Junnila, Jouni and Nordlund, Anders and Hibberd, Ashley and Ouwehand, Arthur C and Ibarra, Alvin},
title = {Effect of an 8‐Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi‐Center, Triple‐Blind, Randomized, Placebo‐Controlled Trial},
journal = {Molecular Nutrition & Food Research},
year = {2025},
doi = {10.1002/mnfr.70081}
}
EUVIMED